The pooled meta-analysis suggests that sodium-glucose cotransporter 2 inhibitors slightly improve hepatic steatosis and fibrosis as compared to controls in adult patients with non-alcoholic fatty liver disease and Type 2 diabetes mellitus with low to moderate certainty of evidence. Here, SLC5A2 is linked to type 2 diabetes mellitus.